Abiopharma

🔍 Humer Franz B (Director)

Company: Allogene Therapeutics, Inc. (ALLO)

Report Date: 2026-06-18

Detailed Transactions and Holdings:

• Acquired 95,400 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 95,400.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.